Detection of AD Biomarkers in Tear Fluid
SmartTears
1 other identifier
observational
69
1 country
1
Brief Summary
Detection of AD biomarkers in tear fluid
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jan 2018
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2020
CompletedFirst Submitted
Initial submission to the registry
November 3, 2020
CompletedFirst Posted
Study publicly available on registry
November 9, 2020
CompletedNovember 9, 2020
November 1, 2020
2 years
November 3, 2020
November 3, 2020
Conditions
Outcome Measures
Primary Outcomes (1)
Level of AD biomarkers in tear fluid
Baseline
Study Arms (4)
Dementia
Dementia
MCI
Mild cognitive impairment
SCD
Subjective cognitive decline
HC
Cognitively healthy control
Interventions
Eligibility Criteria
A total of 60 patients and nine cognitively healthy age-matched controls (HC) were enrolled in this study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Academic Hospital Maastricht
Maastricht, Netherlands
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 3, 2020
First Posted
November 9, 2020
Study Start
January 1, 2018
Primary Completion
January 1, 2020
Study Completion
January 1, 2020
Last Updated
November 9, 2020
Record last verified: 2020-11